regorafenib (BAY 73-4506, Stivarga)
Jump to navigation
Jump to search
Indications
- metastatic colorectal carcinoma
- if previously treated with fluoropyrimidine-, oxaliplatin-, & irinotecan-based chemotherapy, with an anti-VEGF therapy, &, if KRAS wild type, with an anti-EGFR therapy[2]
- advanced gastrointestinal stromal tumors[3]
Storage
- store in orginal container
- must be protected from moisture
- original container has a desiccant
- must be used within 28 days once original container is opened[4]
Mechanism of action
- receptor tyrosine kinase inhibitor
More general terms
References
- ↑ Wikipedia: Regorafenib http://en.wikipedia.org/wiki/Regorafenib
- ↑ 2.0 2.1 FDA Approval for Regorafenib National Cancer Institute http://www.cancer.gov/cancertopics/druginfo/fda-regorafenib
- ↑ 3.0 3.1 FDA News Release: Feb. 25, 2013 FDA approves Stivarga for advanced gastrointestinal stromal tumors http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm340958.htm
- ↑ 4.0 4.1 Prescriber's Letter 21(6): 2014 Oral Meds to Keep in Original Containers Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300622&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Stivarga prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203085lbl.pdf